Đang tải... (xem toàn văn)
Real-world evidence lacks for clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) in Chinese patients.
Wang et al BMC Cancer 2014, 14:940 http://www.biomedcentral.com/1471-2407/14/940 RESEARCH ARTICLE Open Access Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study Yan Wang1, Jianhua Chen2, Shengqi Wu3, Chenping Hu4, Xiaoling Li5, Yuqin Wang5, Yicheng Yang6, Narayan Rajan7, Yun Chen6, Yi Chen8, Zhuanzhuan Luo8 and Wendong Chen9,10* Abstract Background: Real-world evidence lacks for clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) in Chinese patients Methods: Patients receiving first-line chemotherapy for advNS-NSCLC in four Chinese tertiary care hospitals from 2007 to 2012 were retrospectively identified for chart review Propensity score methods created best matched pairs for platinum/pemetrexed versus other platinum-based doublets for head-to-head comparisons of early treatment discontinuation (completed treatment cycles